Smoking and COVID-19: Increased Risk of Severe Complications

Jul.27.2022
Smoking and COVID-19: Increased Risk of Severe Complications
Smoking increases the risk of severe COVID-19 complications and death, according to a study by the American Heart Association.

A new study based on data from the American Heart Association's COVID-19 cardiovascular disease registry has revealed that individuals who smoked or vaped before being hospitalized with COVID-19 are more likely to experience severe complications and even death from SARS-CoV-2 infection compared to those who did not smoke or vape. These findings were published in the peer-reviewed open access scientific journal, PLOS ONE.


Researchers examined data from 107 registered hospitals nationwide on adults aged 18 years and above who were admitted for COVID-19 between January 2020 and March 2021. Smoking status was self-reported, and those who reported using traditional combustible cigarettes or e-cigarette products were classified as smokers without distinction between the two, and without information on smoking duration or previous smoking status. For final analysis, records of 4,086 individuals were selected, with a smoker to nonsmoker ratio of 1:2 (1,362 vs. 2,724), and with no statistical differences in terms of age, gender, race, medical history, or medication between the two groups.


A new study has shown that smoking or using e-cigarettes is linked to more severe cases of COVID-19, regardless of age, gender, race, or medical history.


According to a report, smokers have a 45% higher chance of dying compared to non-smokers, and a 39% higher chance of requiring mechanical ventilation.


While smoking is not related to medical history and drug use, it is a significant risk factor for death in individuals aged 18-59, as well as in Caucasian or obese individuals.


In general, individuals who smoke or use electronic cigarettes often have higher rates of other health conditions and risk factors that could impact how they are affected by COVID-19. However, our research has shown a significant increase in the risk of severe COVID-19, particularly among younger populations, regardless of medical history or drug use. This highlights the urgent need for widespread public health interventions such as anti-smoking campaigns and smoking cessation therapies, especially in the era of COVID-19. "These findings provide the most compelling evidence to date that smokers or users of electronic cigarettes are at higher risk of developing severe COVID-19 and dying from SARS-CoV-2 infection," said Dr. Aruni Bhatnagar, FAHA, senior author of the study and professor of medicine, biochemistry, and molecular biology at the University of Louisville School of Medicine.


Bhatnagar is a co-director of the Tobacco Regulatory Science Center at the American Heart Association, which is partially funded by the United States for this research. The research grants are from the National Institutes of Health and the Food and Drug Administration.


Sandeep R stated, "We established a COVID-19 CVD registry early in the pandemic to better understand the connection between COVID-19 and cardiovascular diseases, particularly in identifying increased risk, in order to provide information to diagnose and care for those at highest risk for complications.


The result of this study has achieved this goal and provided valuable information for individuals and their healthcare teams.


The American Heart Association launched a registry in 2020 to collect specific data on all COVID-19 hospitalized patients as part of the Get With The Guidelines® quality improvement program. All US hospitals caring for adults with active COVID-19 offer free registration and are equipped with infrastructure to support accurate data collection. Between 2020 and June 2022, over 160 hospitals provided data on more than 79,000 patient records.


I am an AI language model designed to generate human-like text. Could you please provide me with the specific text you want me to translate?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s state of Victoria has activated new powers allowing Tobacco Licensing Victoria and police to shut premises suspected of selling, supplying or possessing illicit tobacco for up to 90 days. Longer closures can be ordered by a magistrates’ court. Businesses subject to closure orders must generally cease all trading and will be placed on a public list. Breaching a closure order can carry penalties of up to A$2.5 million and 20 years in prison.
Sep.10
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13